[
  {
    "paragraph": "<p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" id=\"Par3\">Lung cancer is the leading cause of cancer-related death. Nearly 13% of patients with lung cancer are diagnosed with small cell lung cancer (SCLC)<sup><xref ref-type=\"bibr\" rid=\"CR1\">1</xref></sup>. SCLC is a highly aggressive malignancy that is characterized by a short doubling time and tendency to metastasize early. Although patients with newly diagnosed SCLC often achieve dramatic responses to initial treatment with platinum doublet chemotherapy, most patients relapse with rapidly worsening disease that is resistant to further treatment. The median survival in patients with SCLC is ~7 months, and this has not substantially changed in the past few decades\u2014owing to the lack of effective treatment options for patients with relapsed disease<sup><xref ref-type=\"bibr\" rid=\"CR2\">2</xref></sup>. Therefore, understanding the molecular basis of treatment resistance and identifying therapeutic vulnerabilities is necessary to improve outcomes in patients with relapsed SCLC.</p>",
    "section_title": "Introduction",
    "sec_type": "introduction",
    "text": "Lung cancer is the leading cause of cancer-related death. Nearly 13% of patients with lung cancer are diagnosed with small cell lung cancer (SCLC) 1 . SCLC is a highly aggressive malignancy that is characterized by a short doubling time and tendency to metastasize early. Although patients with newly diagnosed SCLC often achieve dramatic responses to initial treatment with platinum doublet chemotherapy, most patients relapse with rapidly worsening disease that is resistant to further treatment. The median survival in patients with SCLC is ~7 months, and this has not substantially changed in the past few decades\u2014owing to the lack of effective treatment options for patients with relapsed disease 2 . Therefore, understanding the molecular basis of treatment resistance and identifying therapeutic vulnerabilities is necessary to improve outcomes in patients with relapsed SCLC.",
    "embedding": 